A phase II study of tamoxifen in ovarian cancer
- PMID: 3709599
- DOI: 10.1016/0277-5379(86)90396-2
A phase II study of tamoxifen in ovarian cancer
Abstract
A phase II study of tamoxifen was conducted in 22 patients with stage III and IV ovarian cancer who had failed chemotherapy and who had evaluable disease. Tamoxifen was administered at a dose of 20 mg twice daily continuously until evidence of progression. Twenty-one patients had progression of disease within 3 months and one patient had stable disease for 6 months. There were no objective responses to this treatment.
MeSH terms
Substances
LinkOut - more resources
Medical